Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now early-phase tilt small index

Cushing Syndrome: early-phase trial registry

5 of 10 indexed Cushing Syndrome trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 5 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Cushing Syndrome: 10 US clinical trials tracked, 5 recruiting.

Cushing Syndrome is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Corcept Therapeutics, running 3 of these trials.

Enrollment posture brief

Registry condition cushing-syndrome

OPEN 5 | RECR 50% | LATE 2 | EARLY 6 | RANK #1724 | SPON 3

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Acute Leukemia of Ambiguous 80%Cushing Syndrome (this)50%Achondroplasia40%Accelerated Phase Chronic My20%Accidental Fall20%
Open-enrollment share among volume-matched conditions near Cushing Syndrome

Cushing Syndrome lists 5 open slots (50% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Cushing Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Cushing Syndrome is recruiting above its size-band peers.

    5 of 10 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Cushing Syndrome research.

    Corcept Therapeutics accounts for 3 of 10 trials (30%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Typical Cushing Syndrome enrolment sits around 125 participants.

    Median target enrolment is 125 among the 10 trials that report a genuine target (sentinel values excluded). 5 of those (50%) plan for fewer than 100 participants.

  4. Cushing Syndrome research is mostly interventional.

    8 interventional and 2 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 24Phase 32

Open and recent trials

10 total, page 1 of 1

RECRUITING 700 participants

Recovery From Cushing Syndrome and Mild Autonomous Cortisol Secretion (MACS)

Mayo Clinic

NCT04543253

RECRUITING 300 participants

Collecting Information About Treatment Results for Patients With Cushing's Syndrome

Memorial Sloan Kettering Cancer Center

NCT03364803

RECRUITING Phase 2 140 participants

Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT06635629

RECRUITING Phase 1 18 participants

A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome

Crinetics Pharmaceuticals

NCT05804669

RECRUITING Phase 2 12 participants

Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome

Recordati Group

NCT03708900

ACTIVE NOT RECRUITING Phase 2 125 participants

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

Corcept Therapeutics

NCT03604198

COMPLETED Phase 3 152 participants

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome

Corcept Therapeutics

NCT03697109

COMPLETED Phase 2 95 participants

New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NCT00001849

COMPLETED Phase 3 51 participants

Open-label Treatment in Cushing's Syndrome

Cortendo AB

NCT03621280

COMPLETED Phase 1 30 participants

Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

Corcept Therapeutics

NCT05347979

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 4
Phase 3 2

Named interventions

Most-linked intervention names on Cushing Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Relacorilant Drug
2 trials
18-FDG Drug
1 trials
CT scan Device
1 trials
Pentetreotide Drug
1 trials
Levoketoconazole Drug
1 trials
relacorilant Drug
1 trials
Dabigatran Etexilate Drug
1 trials
18F-DOPA Drug
1 trials

US sites by state

Facility locations filed on Cushing Syndrome trials. A trial with sites in several states counts in each.

Maryland 6 trials
Florida 5 trials
New York 4 trials
Missouri 3 trials
Illinois 3 trials
Georgia 3 trials
California 3 trials
Ohio 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Cushing Syndrome page

10 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cushing Syndrome condition card totals 10 registered trials; most-linked intervention Relacorilant; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.